Deubiquitinase involved in DNA damage response checkpoint and MYC proto-oncogene stability. Involved in DNA damage induced apoptosis by specifically deubiquitinating proteins of the DNA damage pathway such as CLSPN. Also involved in G2 DNA damage checkpoint, by deubiquitinating CLSPN, and preventing its degradation by the anaphase promoting complex/cyclosome (APC/C). In contrast, it does not deubiquitinate PLK1. Specifically deubiquitinates MYC in the nucleoplasm, leading to prevent MYC degradation by the proteasome: acts by specifically interacting with isoform 1 of FBXW7 (FBW7alpha) in the nucleoplasm and counteracting ubiquitination of MYC by the SCF(FBW7) complex. In contrast, it does not interact with isoform 4 of FBXW7 (FBW7gamma) in the nucleolus, allowing MYC degradation and explaining the selective MYC degradation in the nucleolus. Deubiquitinates ZNF304, hence preventing ZNF304 degradation by the proteasome and leading to the activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) in a subset of colorectal cancers (CRC) cells.
Background References
1. Serra R.W. et. al. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife 3:E02313-E02313(2014).
2. Bassermann F. et. al. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134:256-267(2008).
Sequence Similarity
Belongs to the peptidase C19 family. USP28 subfamily.
Post-translational Modification
Degraded upon nickel ion level or hypoxia exposure.; Phosphorylated upon DNA damage at Ser-67 and Ser-714, by ATM or ATR. Phosphorylated by PRKD1.
Western blot analysis of USP28 on different lysates with Mouse anti-USP28 antibody (EM1901-47) at 1/2,000 dilution.
Lane 1: HeLa (Human cervical adenocarcinoma cell) cell lysate Lane 2: A431 (Human epidermoid carcinoma skin squamous cell) cell lysate Lane 3: 293T (Human embryonic kidney cell) cell lysate Lane 4: SW480 (Human colorectal zdenocarcinoma cell) cell lysate Lane 5: LNCaP (Human prostate cancer cell) cell lysate Lane 6: MDA-MB-231 (Human breast cancer cell) cell lysate Lane 7: MDA-MB-468 (Human breast cancer cells) cell lysate
Blocking: 5% NFDM/TBST, 1 hour at room temperature Primary antibody: EM1901-47, 1/2,000 in 5% NFDM/TBST, overnight at 4 ℃ Secondary antibody: Goat anti-Mouse IgG-HRP (HA1006), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 122 kDa Observed band size: 122 kDa
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"